pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›BUTRANS
drug
save

BUTRANS

Marketedupdated 3mo ago
by Purdue Pharma LP
Approved
community read0 votes

🐶 often sniffed alongside

top 8
  • tagApproval1,664 co-mentions · 579 sources
  • drugSUBLOCADE1,368 co-mentions · 584 sources
  • drugBRIXADI1,296 co-mentions · 584 sources
  • drugbuprenorphine1,291 co-mentions · 584 sources
  • drugbuprenorphine ER1,291 co-mentions · 584 sources
  • drugSUBOXONE1,276 co-mentions · 528 sources
  • drugBUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE1,236 co-mentions · 528 sources
  • drugBUPRENORPHINE HYDROCHLORIDE1,209 co-mentions · 528 sources

all catalysts(26)

approval · 26
Jun 30, 2010
approval
16y ago
BUTRANS (BUPRENORPHINE) — FDA approval
BUTRANS
→
Jul 1, 2011
approval
15y ago
BUTRANS (BUPRENORPHINE) — FDA approval
BUTRANS
→
Jul 1, 2011
approval
15y ago
BUTRANS (BUPRENORPHINE) — FDA approval
BUTRANS
→
Jul 9, 2012
approval
14y ago
BUTRANS (BUPRENORPHINE) — FDA approval
BUTRANS
→
Mar 8, 2013
approval
13y ago
BUTRANS (BUPRENORPHINE) — FDA approval
BUTRANS
→
Apr 15, 2013
approval
13y ago
BUTRANS (BUPRENORPHINE) — FDA approval
BUTRANS
→
Jul 25, 2013
approval
13y ago
BUTRANS (BUPRENORPHINE) — FDA approval
BUTRANS
→
Apr 16, 2014
approval
12y ago
BUTRANS (BUPRENORPHINE) — FDA approval
BUTRANS
→
Jun 30, 2014
approval
12y ago
BUTRANS (BUPRENORPHINE) — FDA approval
BUTRANS
→
Jun 30, 2014
approval
12y ago
BUTRANS (BUPRENORPHINE) — FDA approval
BUTRANS
→
Aug 19, 2014
approval
12y ago
BUTRANS (BUPRENORPHINE) — FDA approval
BUTRANS
→
Jun 26, 2015
approval
11y ago
BUTRANS (BUPRENORPHINE) — FDA approval
BUTRANS
→
Apr 20, 2016
approval
10y ago
BUTRANS (BUPRENORPHINE) — FDA approval
BUTRANS
→
Sep 30, 2016
approval
10y ago
BUTRANS (BUPRENORPHINE) — FDA approval
BUTRANS
→
Dec 16, 2016
approval
10y ago
BUTRANS (BUPRENORPHINE) — FDA approval
BUTRANS
→
May 26, 2017
approval
9y ago
BUTRANS (BUPRENORPHINE) — FDA approval
BUTRANS
→
Aug 14, 2017
approval
9y ago
BUTRANS (BUPRENORPHINE) — FDA approval
BUTRANS
→
Oct 13, 2017
approval
9y ago
BUTRANS (BUPRENORPHINE) — FDA approval
BUTRANS
→
Sep 18, 2018
approval
8y ago
BUTRANS (BUPRENORPHINE) — FDA approval
BUTRANS
→
Sep 18, 2018
approval
8y ago
BUTRANS (BUPRENORPHINE) — FDA approval
BUTRANS
→
Oct 7, 2019
approval
7y ago
BUTRANS (BUPRENORPHINE) — FDA approval
BUTRANS
→
Mar 4, 2021
approval
5y ago
BUTRANS (BUPRENORPHINE) — FDA approval
BUTRANS
→
Jun 17, 2022
approval
4y ago
BUTRANS (BUPRENORPHINE) — FDA approval
BUTRANS
→
Dec 15, 2023
approval
3y ago
BUTRANS (BUPRENORPHINE) — FDA approval
BUTRANS
→
Oct 31, 2024
approval
2y ago
BUTRANS (BUPRENORPHINE) — FDA approval
BUTRANS
→
Dec 22, 2025
approval
8mo ago
BUTRANS (BUPRENORPHINE) — FDA approval
BUTRANS
→
view all 26 catalysts →

Trials studying BUTRANS

  • phase2A Study of Brenipatide in Participants With Opioid Use Disorderrecruitingn=465
  • phase1Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadonerecruitingn=32
  • —Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infantsrecruitingn=1,600
  • phase4Office-based Methadone Versus Buprenorphine to Address Retention in Medication for Opioid Use Disorder Treatment.recruitingn=600
  • phase4Acceptability and Feasibility of Extended-Release Subcutaneous Buprenorphine on a Mobile Pharmacy Clinicnot yet recruitingn=60
  • —Predicting and Preventing Adverse Maternal and Child Outcomes of Opioid Use Disorder in Pregnancyrecruitingn=100
  • —Medication Treatment for Opioid Use Disorder in Expectant Mothers: Infant Neurodevelopmental Outcomes Sub-studycompletedn=71
  • —Medication Treatment for Opioid Use Disorder in Expectant Mothers: Conceptual Model Assessments Sub-studycompletedn=97
more trials →

News(4)

  • Trump administration’s new ‘treatment first’ addiction toolkit emphasizes faith, abstinence
    The White House nods to use of addiction medications but moves away from other harm reduction strategies.
    stat · 2d ago
  • 12 ideas for tackling the U.S. alcohol epidemic
    The U.S. can save lives from excess alcohol use without taking drastic measures. Here are 12 steps that can help.
    stat · 1mo ago
  • Are Republicans turning against medications for treating opioid addiction?
    Federal actions and proposals have reignited debate over methadone and buprenorphine, worrying addiction experts and patient groups.
    stat · 2mo ago
  • Trump administration warns against using federal dollars on fentanyl test strips
    The Trump administration underlines a “clear shift away from harm reduction and practices” that it says facilitates illegal drug use.
    stat · 3mo ago
brand
BUTRANS
generic
BUPRENORPHINE
phase
marketed
Data sources
openFDA · ClinicalTrials.gov
last refreshed 1m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?